UNSPSC 51294910: Tianeptine sodium

This classification denotes a tricyclic antidepressive agent C21H24ClN2O4S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YG0E19592I, chemically known as heptanoic acid, 7-((3-chloro-6,11-dihydro-6-methyl-5,5-dioxidodibenzo(c,f)(1,2)thiazepin-11-yl)amino)-, sodium salt (1:1), but more generally known as tianeptine sodium, which bears US NIH Compound Identifier 23663953. European Medicines Agency schedules Tianeptine sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21398.

Most nations, for tariff and trade purposes, schedule tianeptine sodium under HS 29349990 and SITC 51579. As of Q4 2014, TIANEPTINE SODIUM remains US FDA's Preferred Term for this commodity. SMILES: CN1C2CCCCC2C(C3CCC(CC3S1(=O)=O)CL)NCCCCCCC(=O)[O-].[NA+].

UNSPSC 51294910 Tianeptine sodium is a Commodity code that designates a specific pharmaceutical active ingredient, but recent state and local solicitations tagged under this code show minimal direct procurement of tianeptine itself. Instead, the three recent opportunities posted under this code involve broader pharmaceutical supply and distribution arrangements — naloxone procurement, direct-to-manufacturer prescription programs, and multi-source generic pharmaceutical contracting — none of which explicitly name tianeptine as a product line item. The mismatch between the code's nominal scope and actual buying patterns suggests this code sees limited activity for its stated commodity or that issuing bodies are using the code as a catch-all for pharmaceutical contracting that does not align precisely with tianeptine sodium acquisition.

The recent opportunities span Florida county health systems, Texas state health agencies, and multi-state cooperative purchasing alliances. Seminole County, Florida released an IFB on June 30, 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2023), with quarterly deliveries to the county community health building. The Texas Health and Human Services Commission issued an RFI on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted an RFP on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities, including Oregon, requiring vendor partnerships with three authorized wholesalers and compliance with cGMP and Drug Supply Chain Security Act standards. The geographic spread includes Florida, Texas, Minnesota, and Oregon, with cooperative purchasing extending across multiple jurisdictions. Given the limited direct relevance of recent opportunities to tianeptine sodium specifically, this code warrants monitoring for future pharmaceutical-specific procurement rather than immediate pursuit.